ArticleInternational journal of clinical and experimental pathology2019
Identification of claudin-2, -6, -11 and -14 as prognostic markers in human breast carcinoma.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Claudin-11 Enhances Invasive and Metastatic Abilities of Small-Cell Lung Cancer Through MT1-MMP Activation.Cancer science · 2025Article
- Identification of key genes associated with perineural invasion in stage II colorectal cancer and their prognostic implications.Frontiers in oncology · 2025Article
- The Expression of the Claudin Family of Proteins in Colorectal Cancer.Biomolecules · 2024Review
- Expression of Claudin-9 (CLDN9) in Breast Cancer, the Clinical Significance in Connection with Its Subcoat Anchorage Proteins ZO-1 and ZO-3 and Impact on Drug Resistance.Biomedicines · 2023Article
- Downregulation ofTranslational cancer research · 2023Article
- Identification of key claudin genes associated with survival prognosis and diagnosis in colon cancer through integrated bioinformatic analysis.Frontiers in genetics · 2023Article
- The role and mechanism of claudins in cancer.Frontiers in oncology · 2022Review
- CLDN6 Suppresses c-MYC-Mediated Aerobic Glycolysis to Inhibit Proliferation by TAZ in Breast Cancer.International journal of molecular sciences · 2021Article
- Claudins as biomarkers of differential diagnosis and prognosis of tumors.Journal of cancer research and clinical oncology · 2021Review
- Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review).Molecular medicine reports · 2021Review
- Comprehensive analysis of expression and prognostic value of the claudin family in human breast cancer.Aging · 2021Article
- Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family.Frontiers in genetics · 2021Article
- Epigenetic effects of low-level sodium arsenite exposure on human liver HepaRG cells.Archives of toxicology · 2020Article
- A Quest for New Cancer Diagnosis, Prognosis and Prediction Biomarkers and Their Use in Biosensors Development.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of cancer occurs with various genomic and epigenetic modifications that act as indicators for early diagnosis and treatment. Recent data have shown that the abnormal expression of the claudin (CLDN) tight junction (TJ) proteins is involved in the tumorigenesis of numerous human cancers. Real-time quantitative PCR and western blotting were used to explore the differences in the expression of the CLDN TJ proteins in breast carcinoma tissues and non-neoplastic tissues. The results showed that CLDN5, CLDN9, CLDN12 and CLDN13 were not expressed in breast carcinoma tissues or non-neoplastic tissues. CLDN1, CLDN3, CLDN8 and CLDN10 were expressed in breast carcinoma and non-neoplastic tissues, but there was no significant difference between the expression of these CLDN proteins among them. The expression of CLDN2, -6, -11 and -14 varied between the breast carcinoma and non-neoplastic tissues. Moreover, 86 samples of breast carcinoma and non-neoplastic tissues were examined for the expression of CLDN2, -6, -11 and -14 by streptavidin-peroxidase immunohistochemical staining. The data revealed that the CLDN2, CLDN6, and CLDN14 were expressed in the cell membrane and the expression levels of these proteins were downregulated in breast carcinoma. The CLDN11 was expressed in cell cytoplasm and the expression level of CLDN11 was upregulated compared with those in non-neoplastic tissues. Consistent with these findings, the expression of CLDN2, CLDN6 and CLDN14 were downregulated, while the expression of CLDN11 was upregulated in breast carcinoma compared with those in non-neoplastic tissues. Furthermore, the associations between these CLDNs and clinicopathologic indicators were analyzed, and these CLDN expressions were revealed to be associated with distant metastasis and to predict a poor prognosis. In conclusion, our data showed that the expression levels of CLDN2, -6, -11 and -14 differed between breast carcinoma tissues and histologically non-neoplastic tissues, and the expression levels of these CLDNs may be useful as molecular markers for the diagnosis of breast carcinoma as well as for the determination of metastasis and prognosis.
Indexed as
Identifiers
31934042PMC6949642W3012328236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.